Literature DB >> 6293628

Prolactin binding by human mammary carcinoma: relationship to estrogen receptor protein concentration and patient age.

B Rae-Venter, T Nemoto, S L Schneider, T L Dao.   

Abstract

Biopsy specimens of 55 human mammary carcinomas (38 primary and 17 metastatic) were assayed for prolactin receptors (PrlR). Prolactin bound specifically to 32 (58%) of the tumor biopsy specimens. The apparent Kd for PrlR in individual tumors ranged from 15 pM to 2.3 nM (mean 600 pM, n = 5) and the concentration of PrlR ranged from 0 to 44.5 fmoles/mg protein. Estrogen receptors (ERP) were also detected in 28 of the 32 tumors which had PrlR. Overall, there was no correlation between PrlR and ERP. However, the mean concentration of PrlR was significantly higher (p less than 0.01) in tumors with 6-100 fmoles/mg protein ERP (approximately 13 fmoles PrlR) than in tumors with either less than 6 or greater than 250 fmoles ERP (4.0 +/- 0.4 and 6.5 +/- 1.8 respectively fmoles PrlR). Analysis of PrlR concentration as a function of patient age also showed no overall correlation, but the mean PrlR in tumors from women aged 60-70 was significantly higher (p less than 0.01) than in those from either younger or older women. A higher concentration of PrlR was observed in tumors which were classified histologically as medium or well differentiated (6.1 +/- 1.2 and 11.1 +/- 2.1, respectively) than in those classified as poorly differentiated (3.3 +/- 1.2) (p less than 0.03). There was a negative correlation between PrlR concentration and membrane yield from the tumors (r = 0.43, p less than 0.02). The membrane yield correlated with the ratio of tumor cells to stroma (histologically) (r = 0.63, p less than 0.001). In tumors from 12 patients with metastatic disease on whom follow up after endocrine-related therapy was available, the mean PrlR concentration was significantly higher in the non-responding group (8.2 +/- 3.0) than in the responding group (3.4 +/- 4.2, p = 0.05).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6293628     DOI: 10.1007/bf01806263

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  19 in total

1.  In vitro stimulation of human breast tissue by human prolactin.

Authors:  W G Dilley; S J Kister
Journal:  J Natl Cancer Inst       Date:  1975-07       Impact factor: 13.506

2.  MAMMARY TUMOR INDUCTION BY ESTROGEN OR ANTERIOR PITUITARY HORMONES IN OVARIECTOMIZED RATS GIVEN 7, 12-DIMETHYL-1, 2-BENZANTHRACENE.

Authors:  P K TALWALKER; J MEITES; H MIZUNO
Journal:  Proc Soc Exp Biol Med       Date:  1964-06

3.  Predicting response to endocrine therapy in human breast cancer: a hypothesis.

Authors:  K B Horwitz; W L McGuire
Journal:  Science       Date:  1975-08-29       Impact factor: 47.728

4.  Control of hormone receptor levels and growth of 7,12-dimethylbenz(a)anthracene-induced mammary tumors by estrogens, progesterone and prolactin.

Authors:  J Asselin; P A Kelly; M G Caron; F Labrie
Journal:  Endocrinology       Date:  1977-09       Impact factor: 4.736

5.  Plasma-prolactin in human breast cancer.

Authors:  H G Kwa; M De Jong-Bakker; E Engelsman; F J Cleton
Journal:  Lancet       Date:  1974-03-16       Impact factor: 79.321

6.  Progesterone and progesterone receptors in experimental breast cancer.

Authors:  K B Horwitz; W L McGuire
Journal:  Cancer Res       Date:  1977-06       Impact factor: 12.701

7.  Letter: A breast carcinoma dependent on human placental lactogen.

Authors:  A Barrett; I de Souza; L Morgan; F Tovey; J R Hobbs
Journal:  Lancet       Date:  1975-06-14       Impact factor: 79.321

8.  Prolactin levels in populations at risk for breast cancer.

Authors:  P Hill; E L Wynder; H Kumar; P Helman; G Rona; K Kuno
Journal:  Cancer Res       Date:  1976-11       Impact factor: 12.701

9.  Effect of Ca2+ and salt on forms of estradiol cytoplasmic receptor in human neoplastic breast tissue.

Authors:  S L Schneider; T L Dao
Journal:  Cancer Res       Date:  1977-02       Impact factor: 12.701

10.  Prolactin concentrations in patients with breast cancer.

Authors:  S Franks; D N Ralphs; V Seagroatt; H S Jacobs
Journal:  Br Med J       Date:  1974-11-09
View more
  4 in total

1.  Characterization of prolactin receptors in human breast cancer.

Authors:  J P Peyrat; J Djiane; P A Kelly; B Vandewalle; J Bonneterre; A Demaille
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

Review 2.  Prolactin and breast cancer etiology: an epidemiologic perspective.

Authors:  Shelley S Tworoger; Susan E Hankinson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-02-02       Impact factor: 2.673

3.  Prolactin receptor in primary hyperparathyroidism--expression, functionality and clinical correlations.

Authors:  Felix Haglund; Ming Lu; Vladana Vukojević; Inga-Lena Nilsson; Adam Andreasson; Mensur Džabić; Robert Bränström; Anders Höög; C Christofer Juhlin; Catharina Larsson
Journal:  PLoS One       Date:  2012-05-11       Impact factor: 3.240

4.  Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study.

Authors:  S De Placido; C Gallo; F Perrone; A Marinelli; C Pagliarulo; C Carlomagno; G Petrella; M D'Istria; G Delrio; A R Bianco
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.